References to Primary Literature
- SPRINGER TA: Traffic signals for lymphocyte recircula-tion and leukocyte emigration: the multistep paradigm. Cell (1994) 76:301–314.
- BEVILACQUA MP, NELSON RM: Selectins. J. din. Invest. (1993) 91:379–387.
- MASON JC, HASKARD DO: The clinical importance of leukocyte and endothelial cell adhesion molecules in inflammation. VascuLarMedicine Reviews(1994) 5:249–275.
- BOSSE R, VESTWEBER D: Only simultaneous blocking of the I.- and P-selectin completely inhibits neutrophil migration into mouse peritoneum. Eur. J. Immunol. (1994) 24:3019–3124.
- LABOW MA, NORTON CR, RUMBERGER JM, LOMBARD-GILLOOLY KM, SHUSTER DJ, HUBBARD J, BERTKO R, KNAACK PA, TERRY RW, HARBISON PA, KNOTGEN F, STEWART CL, MCINTYRE KW, WILL PC, BURNS DK, WOLITZKY BA: Characterisation of E-selectin-deficient mice: demonstration of overlapping function of the endothelial selectins. Immunity (1994) 1:709–720.
- MULLIGAN MS, VARANI J, DAME MK, LANE CL, SMITH CW, ANDERSON DC, WARD PA: Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J. Clin. Invest. (1991) 88:1396–1406.
- BINNS RM, LICENCE RM, HARRISON ST, KEELAN ET, RO-BINSON MK, HAS/CARD DO: In vivo E-selectin upregula-tion correlates with early infiltration of PMN, later with PBL-entry: meths block both. Am. J. Phystol. (1996) 270:H183–H193.
- GUNDEL RI-I, WEGNER CD, TORCELLINI CA, CLARICE CC,HAYNES N, ROTHLEIN R, SMITH CW, LETTS LG: Endothe-lial leukocyte adhesion molecule-1 mediates antigen-in-duced acute inflammation and late-phase airway obstruction in monkeys. J. Clin. Invest. (1991) 88:1407–1411.
- KEELAN ET, HARRISON AA, CHAPMAN PT, BINNS RM, PETERS MA, HASKARD DO: Imaging vascular endothelial activation: an approach using radiolabelled mono-clonal antibody against the endothelial cell adhesion molecule E-selectin. J. Nucl. Med. (1994) 35:276–281.
- GEORGE AJT, EPENETOS AA: Advances in antibody engi-neering. Exp. Opin. Ther. Patents (1996) 6:441–456.
- H.YOKOTA T, MILENIC DE, WHITLOW M, SCHLOM J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. (1992) 52:3402–3408.
- LUND J, WINTER G, JONES PT, POUND JD, TANAKA T,WALKER MR, ARTYMIUCK PJ, ARATA Y, BURTON DR, JEFFERIS R et at.: Human FcyRI and FcyRII interact with distinct but overlapping sites on human IgG. J. lin munot (1991) 147:2657–2662.
- ANGAL 5, KING DJ, BODMER MW, TURNER A, LAWSONAD, ROBERTS G, PEDLEY B, ADAIR JR: A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (Ig64) antibody. Mol. Immunol. (1993) 30:105–108.
- RAVETCH JV, KINET JP: Fc receptors. Annu. Rev. Immunol.(1991) 9:457–92.
- KLEIN J: Immunology. Blackwell Scientific Publications, Bos-ton (1990).
References to Patent Literature
- SANDOZ PHARM. CORP., W09504080 (1995).
- ALLERGENE, INC:, W09507933 (1995).
- IMMUNOMEDICS LTD., W09604925 (1996).
- CELLTECH THERAPEUTICS LTD., W09535375 (1995).
- CANCER RES, FUND OF CONTRA COSTA, W09608565 (1996).
- INSERM, W09608564 (1996).
- SCHERING CORP., W09524481 (195).
- SCOTGEN BIOPHARM, INC., W09524482 (1995).
- SCOTGEN BIOPHARM, INC., W09524483 (1995).
- SCOTGEN BIOPHARM, INC., W09524484 (1995).
- PROTEIN DESIGN LABS, INC., EP-682040 (1995).
- SCOTGEN BIOPHARM, INC., W09531546 (1995).
- T CELL SCIENCES, INC., W09516038 (1995).
- CHUGAI SEIYAKU ICK, W09514041 (1995).
- ATHENA NEUROSCIENCES, INC., W09519790 (1995).
- SMITH:KLINE BEECHAM CORP., W09501997 (1995).
- SCOTGEN BIOPHARM, INC., W09506119 (1995).
- SMITHKLINE BEECHAM CORP., W09507301 (1995).
- CELLTECH LTD., W09429351 (1994).